Day: February 1, 2024

Parsippany, NJ, Feb. 01, 2024 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training for more than 75 years, has entered into a sale-leaseback agreement for the property located at 311 Veterans Highway, Levittown, PA. As previously reported, the Company purchased this 90,000 square foot facility in September 2023.  The facility will be the future home of Lincoln Tech’s Philadelphia campus, which is being relocated from its current location at 9191 Torresdale Avenue in Philadelphia, where it has been in operation for more than 60 years.  With this move, the campus will be able to offer additional career training programs and accommodate more students.  The sale transaction is for an aggregate purchase price of approximately $11 million. Simultaneously with...

Featuring Private Performance by Def Jam’s Chase Shakur and LiveZone Red Carpet Interviews with Jeremih, Afgan, thuy, MARIS The Grammy-nominated Splitmind Music Collective has Over 2B Streams across 100+ Major Label Releases LiveOne has streamed over 3k artists to 200+ million viewers , 5 billion engagements Music Fans Across 220 Countries Can Watch on Sunday, February 4 at 5:00 PM ET / 2:00 PM PT on LiveOne.com LOS ANGELES, CA, Feb. 01, 2024 (GLOBE NEWSWIRE) — via NewMediaWire –LiveOne (Nasdaq: LVO), an award-winning, creator-first, music, entertainment and technology platform, announced today that it will stream its 241st edition of LiveOne Presents featuring music industry rising stars during Grammy Awards weekend. The event celebrates LiveOne subsidiary Splitmind’s three Grammy nominations this year. Splitmind is known for...

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company’s pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer. Immuneering will participate in the following investor conferences:Guggenheim 6th Annual Biotechnology Conference (February 7 – 8, 2024)Format: Fireside chat and 1×1 investor meetingsFireside Chat: Wednesday, February 7 from 1:00...

FEDS initial purchase of eBee VISION represents a first in the Middle East WICHITA (Kan.), Feb. 01, 2024 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of full stack drone, sensors and software solutions for customers worldwide in the commercial and government verticals, today announced the Company recently attended the UMEX 2024 Unmanned System Exhibition and Conference January 23-24, 2024 together with FEDS Drone-powered Solutions, a leading drone services and value-added distributor of AgEagle’s high performance unmanned aerial systems. AgEagle interim CEO, Grant Begley, commented, “Opportunities to educate the public safety and security market on the unique value propositions of AgEagle’s leading edge UAS solutions are invaluable. Attending UMEX 2024 alongside FEDS, our trusted partner and customer,...

Accepted for Presentation at the 2024 International Stroke Conference PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been accepted for presentation at the 2024 International Stroke Conference, to be held February 7-9, 2024 in Phoenix, AZ. The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage, will be presented Thursday February 8th during the Ongoing Clinical Trials session of the conference. The...

TruContact Solution Honored for Third Consecutive Year in Telco Innovation Security & Fraud Category CHICAGO, Feb. 01, 2024 (GLOBE NEWSWIRE) — TransUnion announced today it has been named a winner in Juniper Research’s Future Digital Awards for Telco Innovation 2024 for the third year in a row. TruContact™ Spoofed Call Protection received a Gold Award for “Best Robocall Mitigation Solution” in the Security and Fraud Innovation category. Spoofed Call Protection (SCP) enables enterprises to digitally sign their outbound calls, helping to ensure calls aren’t being spoofed or mis-tagged as spam, so customers know and trust who’s calling, and are much more likely to answer the phone. Part of the Trusted Call Solution (TCS) suite, with SCP, spoofed calls can be blocked so they never reach consumers — helping to ensure...

New contract adds to Evtec’s existing order book of $780 million Parts supplied by Evtec to be used in new Jaguar Electric Vehicles to be introduced in 2025 DALLAS, Feb. 01, 2024 (GLOBE NEWSWIRE) — Blackboxstocks Inc. (NASDAQ: BLBX) (“Blackbox” or the “Company”), a financial technology and social media hybrid platform offering real-time proprietary analytics for stock and options traders, announced today that its planned acquisition target Evtec Aluminium Limited, (“Evtec”) has been awarded a long term supply contract from JLR, previously Jaguar Land Rover, to supply parts for a new line of Jaguar electric vehicles. As a world class manufacturer of lightweight aluminum parts for the EV, luxury and performance automotive market, Evtec has been designated as the new single-source supplier for key components in the EV power train...

WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the collaboration. The scientific collaboration includes the Company’s lead product candidate istaroxime and the next generation compounds called SERCA2a activators. One of istaroxime’s mechanisms of action is facilitation of myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake...

BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) —  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O’Rear will not stand for reelection to the Company’s Board of Directors at the Company’s 2024 annual meeting of stockholders.  Mr. O’Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. “Sam has been invaluable to the Board and to me personally since the inception of Sensus Healthcare more than a decade ago.  I wish him the same success in his...

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at the 20th Annual WORLDSymposium™, which will be held February 4-9, 2024, in San Diego, California. WORLDSymposium™ Presentation Details on DNL310 and DNL126 Presentations on DNL310 will include new two-year data on clinical outcomes and previously presented data on biomarkers from the ongoing Phase 1/2 study in MPS II. In addition, an oral presentation...